[Skip to Content]
[Skip to Content Landing]
October 19, 1957


Author Affiliations

Arequipa, Peru

JAMA. 1957;165(7):829-830. doi:10.1001/jama.1957.72980250004014b

Laboratory evidence indicates that Camoform [biallylamicol, PAA-701, SN 6771, 6,6′-diallyl-a, a′-bis(diethylamino)-4,4′-bi-o-cresol dihydrochloride] is effective against Entamoeba histolytica in vitro. Administered orally to animals infected with E. histolytica, the drug is effective against intestinal amebiasis in rats and dogs, and amebic hepatitis in hamsters. Prophylactic oral administration of the drug confers protection against hepatic and pulmonary amebiasis in hamsters. The drug is also relatively nontoxic in animals after short-term administration, is rapidly absorbed, is stored in high concentration in the liver and lung (the most frequent sites of extraintestinal amebiasis), and is slowly excreted largely by way of the bile (resulting in prolonged fecal levels).1

Clinically it has been shown in a previous paper2 to produce a rapid therapeutic response and cure in 82 of 85 patients with acute amebic colitis. Among 145 chronic cases, 112 were completely cured with one course of treatment, and 29